Nesiritide in Transplant-Eligible Management of Congestive Heart Failure-TMAC - Related Studies

Nesiritide in Transplant-Eligible Management of Congestive Heart Failure-TMAC

This study has been terminated.

Study NCT00338455. Last updated on May 15, 2008. Information provided by Scios R&D, Inc.

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Renal Insufficiency.
		Dialysis
		Congestive Heart Failure
		Cardiac Transplantation
		Renal Failure

2	Additional conditions recognized in this trial
		Heart Failure
		Kidney Failure
		Renal Insufficiency

3	More general conditions related to this trial
		Cardiovascular Diseases
		Heart Diseases
		Kidney Diseases
		Urologic Diseases

4	Additional drug interventions recognized in this trial
		Dobutamine
		Milrinone
		Natriuretic Peptide, Brain

5	More general drug interventions related to this trial
		Adrenergic Agents
		Adrenergic Agonists
		Adrenergic beta-Agonists
		Autonomic Agents
		Cardiotonic Agents
		Cardiovascular Agents
		Enzyme Inhibitors
		Hematologic Agents
		Molecular Mechanisms of Pharmacological Action
		Natriuretic Agents
		Neurotransmitter Agents
		Peripheral Nervous System Agents
		Pharmacologic Actions
		Phosphodiesterase Inhibitors
		Physiological Effects of Drugs
		Platelet Aggregation Inhibitors
		Protective Agents
		Sympathomimetics
		Therapeutic Uses
		Vasodilator Agents

6	Sponsors listed in this trial
		Scios R&, Inc.